Before COVID, India’s diagnostic antibody market was fragmented and import‑dependent. Then the pandemic hit, and local manufacturers like Transasia and Mylab started producing antibody rapid tests at scale. The India antibodies market research study shows that the diagnostic segment is now growing at over 20% annually, driven by a boom in pathology labs and government screening programs for tuberculosis, hepatitis, and even cancer.

What’s changed? The government now mandates that many diagnostic tests use locally manufactured antibodies, reducing reliance on Chinese imports. The India antibodies market analysis highlights that polyclonal antibodies (used in many diagnostic kits) are the fastest‑growing type, because they’re cheaper and easier to produce than monoclonals.

But quality remains an issue. Some Indian diagnostic kits have variable sensitivity and specificity, leading to false results. The regulator (CDSCO) is now cracking down, demanding ISO certification and clinical validation.

The bottom line: India has the potential to become a diagnostic antibody hub for the Global South. But it needs to invest in quality control, not just volume.